ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer
Status:
Terminated
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare progression-free survival in patients with advanced
ovarian cancer treated with ZD4054 in combination with carboplatin+paclitaxel versus placebo
in combination with carboplatin+paclitaxel.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Collaborator:
ISTITUTO REGINA ELENA - CENTRO RICERCHE SPERIMENTALI